A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the “EpiVacCorona” Vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (phase I–II)
Vaccination of the population is one of the most effective countermeasures in responding to the pandemic caused by novel coronavirus infection. Therefore, scientists all over the world have been working to develop effective and safe vaccines. We have developed a synthetic peptide vaccine, EpiVacCoro...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | RU |
| Publicado: |
Sankt-Peterburg : NIIÈM imeni Pastera
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/7df779e259364aabaefcf269dea25ef1 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:7df779e259364aabaefcf269dea25ef1 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:7df779e259364aabaefcf269dea25ef12021-11-22T07:09:55ZA single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the “EpiVacCorona” Vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (phase I–II)2220-76192313-739810.15789/2220-7619-ASB-1699https://doaj.org/article/7df779e259364aabaefcf269dea25ef12021-03-01T00:00:00Zhttps://www.iimmun.ru/iimm/article/view/1699https://doaj.org/toc/2220-7619https://doaj.org/toc/2313-7398Vaccination of the population is one of the most effective countermeasures in responding to the pandemic caused by novel coronavirus infection. Therefore, scientists all over the world have been working to develop effective and safe vaccines. We have developed a synthetic peptide vaccine, EpiVacCorona, against novel SARS-CoV-2 coronavirus, which is a suspension for intramuscular administration containing a composition of chemically synthesized peptide immunogens of the S protein of SARS-CoV-2 coronavirus conjugated to a carrier protein and adsorbed on aluminum hydroxide. Phase I–II clinical trials of the vaccine have started that consist of two stages: Stage 1 is an open study of the safety, reactogenicity, and immunological activity of the vaccine with the involvement of 14 volunteers aged 18–30 years; Stage 2 is a single blind, comparative, randomized placebo-controlled study with the involvement of 86 volunteers. The study involved volunteers aged 18–60 years; the vaccine was injected intramuscularly twice, spaced 21 days apart between injections. All local reactions in response to vaccine administration were mild, such as a short-term pain at the injection site. There were no signs of development of local or systemic adverse reactions. The two-dose vaccination scheme induced the production of antibodies, specific to the antigens that make up the vaccine, in 100% of the volunteers. Seroconversion with a neutralizing antibody titer ≥ 1:20 was reported in 100% of the volunteers 21 days following the second immunization dose. No seroconversion was reported in the groups of volunteers vaccinated with a placebo. The peptide-based EpiVacCorona Vaccine has low reactogenicity and is a safe, immunogenic product. Clinical Trials Identifier: NCT04527575.A. B. RyzhikovЕ. А. RyzhikovM. P. BogryantsevaS. V. UsovaE. D. DanilenkoE. A. NechaevaO. V. PyankovO. G. PyankovaA. S. GudymoS. A. BodnevG. S. OnkhonovaE. S. SleptsovaV. I. KuzubovN. N. RyndyukZ. I. GinkoV. N. PetrovA. A. MoiseevaP. Yu. TorzhkovaS. A. PyankovT. V. TregubchakD. V. AntonecE. V. GavrilovaR. A. MaksyutovSankt-Peterburg : NIIÈM imeni Pasteraarticleepivaccoronapeptide vaccineclinical trialscovid-19coronavirusInfectious and parasitic diseasesRC109-216RUInfekciâ i Immunitet, Vol 11, Iss 2, Pp 283-296 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
RU |
| topic |
epivaccorona peptide vaccine clinical trials covid-19 coronavirus Infectious and parasitic diseases RC109-216 |
| spellingShingle |
epivaccorona peptide vaccine clinical trials covid-19 coronavirus Infectious and parasitic diseases RC109-216 A. B. Ryzhikov Е. А. Ryzhikov M. P. Bogryantseva S. V. Usova E. D. Danilenko E. A. Nechaeva O. V. Pyankov O. G. Pyankova A. S. Gudymo S. A. Bodnev G. S. Onkhonova E. S. Sleptsova V. I. Kuzubov N. N. Ryndyuk Z. I. Ginko V. N. Petrov A. A. Moiseeva P. Yu. Torzhkova S. A. Pyankov T. V. Tregubchak D. V. Antonec E. V. Gavrilova R. A. Maksyutov A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the “EpiVacCorona” Vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (phase I–II) |
| description |
Vaccination of the population is one of the most effective countermeasures in responding to the pandemic caused by novel coronavirus infection. Therefore, scientists all over the world have been working to develop effective and safe vaccines. We have developed a synthetic peptide vaccine, EpiVacCorona, against novel SARS-CoV-2 coronavirus, which is a suspension for intramuscular administration containing a composition of chemically synthesized peptide immunogens of the S protein of SARS-CoV-2 coronavirus conjugated to a carrier protein and adsorbed on aluminum hydroxide. Phase I–II clinical trials of the vaccine have started that consist of two stages: Stage 1 is an open study of the safety, reactogenicity, and immunological activity of the vaccine with the involvement of 14 volunteers aged 18–30 years; Stage 2 is a single blind, comparative, randomized placebo-controlled study with the involvement of 86 volunteers. The study involved volunteers aged 18–60 years; the vaccine was injected intramuscularly twice, spaced 21 days apart between injections. All local reactions in response to vaccine administration were mild, such as a short-term pain at the injection site. There were no signs of development of local or systemic adverse reactions. The two-dose vaccination scheme induced the production of antibodies, specific to the antigens that make up the vaccine, in 100% of the volunteers. Seroconversion with a neutralizing antibody titer ≥ 1:20 was reported in 100% of the volunteers 21 days following the second immunization dose. No seroconversion was reported in the groups of volunteers vaccinated with a placebo. The peptide-based EpiVacCorona Vaccine has low reactogenicity and is a safe, immunogenic product. Clinical Trials Identifier: NCT04527575. |
| format |
article |
| author |
A. B. Ryzhikov Е. А. Ryzhikov M. P. Bogryantseva S. V. Usova E. D. Danilenko E. A. Nechaeva O. V. Pyankov O. G. Pyankova A. S. Gudymo S. A. Bodnev G. S. Onkhonova E. S. Sleptsova V. I. Kuzubov N. N. Ryndyuk Z. I. Ginko V. N. Petrov A. A. Moiseeva P. Yu. Torzhkova S. A. Pyankov T. V. Tregubchak D. V. Antonec E. V. Gavrilova R. A. Maksyutov |
| author_facet |
A. B. Ryzhikov Е. А. Ryzhikov M. P. Bogryantseva S. V. Usova E. D. Danilenko E. A. Nechaeva O. V. Pyankov O. G. Pyankova A. S. Gudymo S. A. Bodnev G. S. Onkhonova E. S. Sleptsova V. I. Kuzubov N. N. Ryndyuk Z. I. Ginko V. N. Petrov A. A. Moiseeva P. Yu. Torzhkova S. A. Pyankov T. V. Tregubchak D. V. Antonec E. V. Gavrilova R. A. Maksyutov |
| author_sort |
A. B. Ryzhikov |
| title |
A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the “EpiVacCorona” Vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (phase I–II) |
| title_short |
A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the “EpiVacCorona” Vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (phase I–II) |
| title_full |
A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the “EpiVacCorona” Vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (phase I–II) |
| title_fullStr |
A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the “EpiVacCorona” Vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (phase I–II) |
| title_full_unstemmed |
A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the “EpiVacCorona” Vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (phase I–II) |
| title_sort |
single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the “epivaccorona” vaccine for the prevention of covid-19, in volunteers aged 18–60 years (phase i–ii) |
| publisher |
Sankt-Peterburg : NIIÈM imeni Pastera |
| publishDate |
2021 |
| url |
https://doaj.org/article/7df779e259364aabaefcf269dea25ef1 |
| work_keys_str_mv |
AT abryzhikov asingleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT earyzhikov asingleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT mpbogryantseva asingleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT svusova asingleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT eddanilenko asingleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT eanechaeva asingleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT ovpyankov asingleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT ogpyankova asingleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT asgudymo asingleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT sabodnev asingleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT gsonkhonova asingleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT essleptsova asingleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT vikuzubov asingleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT nnryndyuk asingleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT ziginko asingleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT vnpetrov asingleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT aamoiseeva asingleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT pyutorzhkova asingleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT sapyankov asingleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT tvtregubchak asingleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT dvantonec asingleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT evgavrilova asingleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT ramaksyutov asingleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT abryzhikov singleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT earyzhikov singleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT mpbogryantseva singleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT svusova singleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT eddanilenko singleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT eanechaeva singleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT ovpyankov singleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT ogpyankova singleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT asgudymo singleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT sabodnev singleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT gsonkhonova singleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT essleptsova singleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT vikuzubov singleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT nnryndyuk singleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT ziginko singleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT vnpetrov singleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT aamoiseeva singleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT pyutorzhkova singleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT sapyankov singleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT tvtregubchak singleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT dvantonec singleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT evgavrilova singleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii AT ramaksyutov singleblindplacebocontrolledrandomizedstudyofthesafetyreactogenicityandimmunogenicityoftheepivaccoronavaccineforthepreventionofcovid19involunteersaged1860yearsphaseiii |
| _version_ |
1718417926241910784 |